MedTrace Logo

Study of EVO756 in Adults With Migraine

NCT07616128 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2026-06-01

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.

Conditions

Interventions

DRUG

EVO756, Dose 1

Orally administered EVO756, Dose 1 (Daily)

DRUG

EVO756, Dose 2

Orally administered EVO756, Dose 2 (Daily)

DRUG

Placebo

Placebo Control (Daily)

Sponsors & Collaborators

  • Evommune, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-10-31
Completion
2027-11-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07616128 on ClinicalTrials.gov